4-(4-chloro-benzhydryl)-piperazin-1-ylamine | 1698-33-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-chloro-benzhydryl)-piperazin-1-ylamine
• 英文别名: 4-[(4-Chlorophenyl)-phenylmethyl]piperazin-1-amine
• CAS: 1698-33-5
• 化学式: C₁₇H₂₀ClN₃
• 分子量: 301.819
• InChiKey: OGQSEFKYZSRIQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 20-Deoxyrosaramicin derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：SCHERING CORPORATION

  公开号：EP0042570B1

  公开（公告）日：1983-10-19
• US4279896A
  申请人：——

  公开号：US4279896A

  公开（公告）日：1981-07-21
• [EN] CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE<br/>[FR] PRÉPARATION SOUS FORME DE CAPSULE COMPRENANT DU MONTÉLUKAST ET DE LA LÉVOCÉTIRIZINE
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2013012199A1

  公开（公告）日：2013-01-24

  Disclosed is a capsule formulation for preventing or treating allergic rhinitis and asthma, which comprises two separate layers of: (1) a Montelukast layer comprising montelukast or a pharmaceutically acceptable salt thereof; and (2) a Levocetirizine layer comprising levocetirizine or a pharmaceutically acceptable salt thereof; and a method for the preparation thereof. The capsule formulation according to the present invention can completely separate two active ingredients, thereby minimizing the reactivity between them and improving product stability against aging effects, and thus, can optimize the therapeutic effects.